TrialEsophagus : official journal of the Japan Esophageal Society2022

Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181.

Kei Muro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.